Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Ocera Therapeutics, Inc. | a14-8078_1ex99d1.htm |
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 13, 2014
OCERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE |
|
001-35119 |
|
63-1192270 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
of |
|
|
|
Identification No.) |
|
incorporation) |
|
|
|
|
|
525 University Avenue, Suite 610 |
|
|
|
Palo Alto, CA |
|
94301 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (650) 475-0150
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On March 13, 2014, Ocera Therapeutics, Inc. issued a press release announcing its financial results and other information for the quarter and year ended December 31, 2013. The full text of the press release and the related attachments are furnished as Exhibit 99.1 hereto and incorporated herein by reference.
The information under this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release of Ocera Therapeutics, Inc. dated March 13, 2014, furnished hereto. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
March 13, 2014 |
Ocera Therapeutics, Inc. | |
|
|
|
|
|
|
By: |
/s/ Linda S. Grais, M.D. |
|
|
Name: |
Linda S. Grais, M.D. |
|
|
Title: |
President and Chief Executive Officer |